Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
-
Authors :
Wylie AA; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.; Schoepfer J
Subjects: Allosteric Site/Allosteric Site/Allosteric Site/*drug effects ; Fusion Proteins, bcr-abl/Fusion Proteins, bcr-abl/Fusion Proteins, bcr-abl/*antagonists & inhibitors ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/Leukemia, Myelogenous, Chronic, BCR-ABL Positive/Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
-
Source:
Nature [Nature] 2017 Mar 30; Vol. 543 (7647), pp. 733-737. Date of Electronic Publication: 2017 Mar 22.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited
Record details
-
Authors :
Jazayeri A; Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, UK.; Doré AS
Subjects: Pyrazoles/Pyrazoles/Pyrazoles/*metabolism ; Receptors, Glucagon/Receptors, Glucagon/Receptors, Glucagon/*antagonists & inhibitors ; Receptors, Glucagon/Receptors, Glucagon/Receptors, Glucagon/*chemistry
-
Source:
Nature [Nature] 2016 May 12; Vol. 533 (7602), pp. 274-7. Date of Electronic Publication: 2016 Apr 25.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited
Record details